Master Regimen · v6.16 / rev 7.20 · 2026-07-22

Protocol Hub

Post-Frey recovery · live window 7/22 → 8/1 · canonical IF returns ~Aug 1

This revision
59 readings · 1 central claim struck
rev 7.20 — the blood-pressure re-baseline.

The postprandial fall was max-fasted minus min-postprandial across different days. Paired, every day runs the other way: +3.4 mmHg. Pulse pressure has dropped 69.7 → 54.3, which is exactly what the anemia hypothesis predicted. No dose amount changed. One supplement moved slot.

Today

rev 7.20
Daily architecture
The full time spine. Agmatine now at 4 PM. Infini-B B6 line corrected.
59 readings
Blood pressure
Re-baselined on 59 readings. Fasted AM now 120.8/66.5 at 40 mg. The 80 mg case has evaporated.
Instrument
CGM + glucometer
Low alerts ON. Fingerstick over-reads at Hct 25.2 — check the meter first. Glucagon premise is UNMEASURABLE.
Gate board
What comes back, when
ProBiota 7/21 · SPM 8/1 · MegaSpore 8/5 · Turkey Tail 8/8 · Cordyceps 8/19.
Only what decides
Measurement plan
Iron · PT/INR · hyponatremia panel · copper + ceruloplasmin (new). Nothing decorative.
Scripts
Clinical facts to obtain
Exactly what only Kuhlman and Wancata can produce — with the words to use.

The DAO correction

What actually governs DAO

DAO (diamine oxidase) is the histamine-degrading enzyme. Its cofactors are copper · calcium · topaquinone (TPQ) — not B6. Ranked for this phenotype, the real levers are:

1. Substrate competition — Agmatine 1 g/day is a confirmed DAO substrate (moved to 4 PM to clear the NaturDAO collision). · 2. Mucosal integrity — DAO is made by gut-lining cells; post-Frey + ulcers + EPI is the likely suppressor. Intervention already live: L-Glutamine 15 g/day. · 3. Copper — the actual metal cofactor, now added to the 8/1 draw.

⚠ B6 is not a DAO lever — it's upstream on histamine synthesis (histidine decarboxylase). Do not switch to NaturDAO Plus: it bundles P5P on the same retired rationale.

Standing constraints

Never

Acetaminophen — documented adverse, VM July 2026  ·  NSAIDs — ulcer / GI-bleed history  ·  Soy — stops Creon working (SerinAid PS is the exception: lecithin lipid fraction, no trypsin inhibitors)  ·  Potassium supplements — on the ARB

Call the team — not a supplement question

Dark or tarry stool · visible blood · new dizziness · resting HR climbing · fever or rigors · any BP reading ≥180/120 → urgent care, not a message

Clinical interpreter note

The regimen produces atypically suppressed inflammatory markers (WBC, CRP). Clinical suspicion outweighs standard lab thresholds when assessing acute infection, cholangitis, or pancreatitis flare. A normal white count does not exclude infection in this patient.

What the audits did not find

The regimen was never on trial

Adversarial passes have lodged zero findings against the chronic core. Not one of the ~40 compounds was faulted on evidence quality, dose, timing, interaction, or sourcing — outside the post-surgical window. What gets corrected are the overlays, the instruments, and the reasoning — all of which sit around the regimen, not in it. This rev is one more of those: a stated rationale was wrong; the compound stayed.

The record: GMI 5.7–5.8% across 180 days · zero readings above 250 · eGFR 112 · normal hepatic function despite an obstruction history · HbA1c 6.1% in T3c diabetes, without insulin.

Master Regimen · v6.16 / rev 7.20 · 2026-07-22
Supersedes rev 7.18. DAO-cofactor rationale struck (Cu·Ca·TPQ, not PLP). Standalone P5P rejected.
Agmatine 2 PM → 4 PM (timing only). Copper + ceruloplasmin added to the 8/1 draw.
Supplement-layer decisions rest with Nate. Clinical-status + prescribed-med changes are the care team's.